News

A new simulation model-based decision tool may be able to support discussion about genomic testing and early breast cancer treatment through its ability to integrate clinicopathologic features, comorbidities, and genomic information.

Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...

A recent study found disparities in health care resource utilization and costs across first-line therapy regimens for patients with metastatic melanoma, noting highest utilization rates in regimens containing ipilimumab.

A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.

Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.

VTE prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy, according to a recent cost-effectiveness analysis.

A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.

Atezolizumab plus bevacizumab was not considered cost-effective compared with sorafenib for the treatment of unresectable or metastatic HCC, although associated with clinical benefit.

A recent study revealed that prophylactic cranial irradiation is not cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.

Study findings highlight substantial economic burden incurred by Medicare among patients with CLL who initiated systemic therapy in routine practice, citing adverse events as a large contributor to the high overall cost of CLL management.